Table 2.
The association between pretreatment NLR, DNLR, LMR, and PLR values and clinicopathological parameters (n=26)
| Parameters | NLR
|
DNLR
|
LMR
|
PLR
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | <4.8 | ≥4.8 | P-value | <3.1 | ≥3.1 | P-value | <3.6 | ≥3.6 | P-value | <195 | ≥195 | P-value | |
|
| |||||||||||||
| Gender | |||||||||||||
| Female | 14 | 9 | 5 | 0.462 | 9 | 5 | 0.756 | 7 | 7 | 0.248 | 5 | 9 | 0.683 |
| Male | 12 | 6 | 6 | 7 | 5 | 3 | 9 | 3 | 9 | ||||
| Age (years) | |||||||||||||
| <65 | 22 | 10 | 12 | 0.446 | 9 | 13 | 0.547 | 9 | 13 | 1.000 | 6 | 16 | 0.563 |
| ≥65 | 4 | 1 | 3 | 1 | 3 | 1 | 3 | 2 | 2 | ||||
| Grade | |||||||||||||
| II | 9 | 5 | 4 | 0.873 | 6 | 3 | 0.696 | 3 | 6 | 0.046 | 3 | 6 | 1.000 |
| III | 17 | 10 | 7 | 10 | 7 | 13 | 4 | 5 | 12 | ||||
| Initial response | |||||||||||||
| Regression/stable | 13 | 9 | 4 | 0.234 | 11 | 2 | 0.041 | 6 | 7 | 0.420 | 10 | 3 | 0.673 |
| Progression | 13 | 6 | 7 | 5 | 8 | 4 | 9 | 8 | 5 | ||||
| Progression | |||||||||||||
| Yes | 19 | 9 | 10 | 0.178 | 9 | 10 | 0.023 | 12 | 7 | 1.000 | 8 | 11 | 0.062 |
| No | 7 | 6 | 1 | 7 | 0 | 4 | 3 | 0 | 7 | ||||
| Status | |||||||||||||
| living | 7 | 6 | 1 | 0.178 | 7 | 0 | 0.023 | 4 | 3 | 1.000 | 0 | 7 | 0.062 |
| Deceased | 19 | 9 | 10 | 9 | 10 | 12 | 7 | 8 | 11 | ||||
Note: Fisher’s exact test was used if expected minimum was <5 with chi-squared test. Bold values indicate statistical significance.
Abbreviations: DNLR, derived neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; PLR: platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio.